The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Hexastat     N2,N2,N4,N4,N6,N6-hexamethyl- 1,3,5...

Synonyms: Hexalen, Hexinawas, Hemel, altretamine, HEXAMETHYLMELAMINE, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of HEXAMETHYLMELAMINE

 

Psychiatry related information on HEXAMETHYLMELAMINE

 

High impact information on HEXAMETHYLMELAMINE

 

Chemical compound and disease context of HEXAMETHYLMELAMINE

 

Biological context of HEXAMETHYLMELAMINE

 

Anatomical context of HEXAMETHYLMELAMINE

 

Associations of HEXAMETHYLMELAMINE with other chemical compounds

 

Gene context of HEXAMETHYLMELAMINE

 

Analytical, diagnostic and therapeutic context of HEXAMETHYLMELAMINE

References

  1. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack? Edmonson, J.H., Wieand, H.S., McCormack, G.W. J. Natl. Cancer Inst. (1988) [Pubmed]
  2. Comparison of DNA damage by methylmelamines and formaldehyde. Ross, W.E., McMillan, D.R., Ross, C.F. J. Natl. Cancer Inst. (1981) [Pubmed]
  3. Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors. Lake, L.M., Grunden, E.E., Johnson, B.M. Cancer Res. (1975) [Pubmed]
  4. Hexamethylmelamine-induced regression of human lung tumors growing in immune deprived mice. Mitchley, B.C., Clarke, S.A., Connors, T.A., Neville, A.M. Cancer Res. (1975) [Pubmed]
  5. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Lee, C.R., Faulds, D. Drugs (1995) [Pubmed]
  6. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Lee, C.R., Nicholson, P.W., Ledermann, J.A., Rustin, G.J. Eur. J. Gynaecol. Oncol. (1996) [Pubmed]
  7. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. Levin, L., Simon, R., Hryniuk, W. J. Natl. Cancer Inst. (1993) [Pubmed]
  8. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. Rustin, G.J., Nelstrop, A.E., Crawford, M., Ledermann, J., Lambert, H.E., Coleman, R., Johnson, J., Evans, H., Brown, S., Oster, W. J. Clin. Oncol. (1997) [Pubmed]
  9. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation. Ames, M.M., Richardson, R.L., Kovach, J.S., Moertel, C.G., O'Connell, M.J. Cancer Res. (1990) [Pubmed]
  10. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). Judson, I.R., Calvert, A.H., Rutty, C.J., Abel, G., Gumbrell, L.A., Graham, M.A., Evans, B.D., Wilman, D.E., Ashley, S.E., Cairnduff, F. Cancer Res. (1989) [Pubmed]
  11. Pharmacokinetics of hexamethylmelamine in intralipid following hepatic regional administration in rabbits. Gordon, I.L., Kar, R., Opfell, R.W., Wile, A.G. Cancer Res. (1987) [Pubmed]
  12. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. Levin, L., Hryniuk, W.M. J. Clin. Oncol. (1987) [Pubmed]
  13. Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. Green, M., Horton, C., Spaulding, M., Silver, R.T., Berenberg, J., Kennedy, B.J., Pajak, T.F., Comis, R. J. Clin. Oncol. (1983) [Pubmed]
  14. Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. Bruckner, H.W., Kalman, J., Spigelman, M., Gorbaty, M.I., Butwell, N., Storch, J., McKenna, A. Oncology (1989) [Pubmed]
  15. A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Kristensen, G.B., Baekelandt, M., Vergote, I.B., Tropé, C. Eur. J. Cancer (1995) [Pubmed]
  16. A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. Olver, I., Davy, M., Lüftner, D., Park, S.H., Egorin, M., Ellis, A., Webster, L. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  17. Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism. Klippert, P.J., Hulshoff, A., Mingels, M.J., Hofman, G., Noordhoek, J. Cancer Res. (1983) [Pubmed]
  18. Cellular and subcellular studies of the biotransformation of hexamethylmelamine in rat isolated hepatocytes and intestinal epithelial cells. Borm, P.J., Mingels, M.J., Frankhuijzen-Sierevogel, A.C., van Graft, M., Hulshoff, A., Noordhoek, J. Cancer Res. (1984) [Pubmed]
  19. Hexamethylmelamine is a potent inducer of deletions in male germ cells of Drosophila melanogaster. Aguirrezabalaga, I., Nivard, M.J., Comendador, M.A., Vogel, E.W. Carcinogenesis (1995) [Pubmed]
  20. Reproduction and teratology studies on hexamethylmelamine in the rat and rabbit. Thompson, D.J., Dyke, I.L., Molello, J.A. Toxicol. Appl. Pharmacol. (1984) [Pubmed]
  21. Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine. Ames, M.M., Sanders, M.E., Tiede, W.S. Cancer Res. (1983) [Pubmed]
  22. Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines. Miller, K.J., McGovern, R.M., Ames, M.M. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  23. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide. D'Incalci, M., Torti, L., Damia, G., Erba, E., Morasca, L., Garattini, S. Cancer Res. (1983) [Pubmed]
  24. The role of hexamethylmelamine in the management of ovarian cancer. Schein, P.S., Scheffler, B., McCulloch, W. Cancer Treat. Rev. (1991) [Pubmed]
  25. Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy, and second-look laparotomy. Greiner, R., Goldhirsch, A., Davis, B.W., Dreher, E., Peyer, T., Locher, G., Neuenschwander, H., Joss, R., Brunner, K., Veraguth, P. J. Cancer Res. Clin. Oncol. (1984) [Pubmed]
  26. Studies and characterization of a murine neuroblastoma model. Keogh, B., Chu, T.M., Williams, P., Moore, R.H., Murphy, G.P. Journal of surgical oncology. (1976) [Pubmed]
  27. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). Vogl, S.E., Berenzweig, M., Kaplan, B.H., Moukhtar, M., Bulkin, W. Cancer treatment reports. (1979) [Pubmed]
  28. Hexamethylmelamine (altretamine) in small cell lung cancer (SCLC). Comis, R.L. Cancer Treat. Rev. (1991) [Pubmed]
  29. Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Goldhirsch, A., Greiner, R., Dreher, E., Sessa, C., Krauer, F., Forni, M., Jungi, F.W., Brunner, K.W., Veraguth, P., Engeler, V. Cancer (1988) [Pubmed]
  30. A newly developed hexamethylmelamine derivative, SAE9 with both antitumor and aromatase-inhibitory activity. Tanino, H., Kubota, T., Yamada, Y., Koh, J.I., Takeuchi, T., Kase, S., Furukawa, T., Takahashi, M., Fukuda, S., Ogose, N. Anticancer Res. (1993) [Pubmed]
  31. Testing of medical electrical and hospital laboratory equipment: DHSS recognition of the BSI Test House, Hemel Hempstead. Rogers, R.T. Journal of medical engineering & technology. (1980) [Pubmed]
  32. Clinical pharmacokinetics of altretamine. Damia, G., D'Incalci, M. Clinical pharmacokinetics. (1995) [Pubmed]
  33. Hexamethylmelamine: activity in lymphoma and other tumors. Macdonald, J.S. Cancer Treat. Rev. (1991) [Pubmed]
  34. In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts. Tanino, H., Kubota, T., Yamada, Y., Koh, J., Kase, S., Furukawa, T., Kuo, T.H., Saikawa, Y., Kitajima, M., Naito, Y. Jpn. J. Cancer Res. (1995) [Pubmed]
  35. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. Kerr, J.R., Cunniffe, V.S., Kelleher, P., Coats, A.J., Mattey, D.L. J. Med. Virol. (2004) [Pubmed]
 
WikiGenes - Universities